WO1998017315A3 - Permeation enhancers for transdermal drug delivery compositions, devices, and methods - Google Patents

Permeation enhancers for transdermal drug delivery compositions, devices, and methods Download PDF

Info

Publication number
WO1998017315A3
WO1998017315A3 PCT/US1997/018956 US9718956W WO9817315A3 WO 1998017315 A3 WO1998017315 A3 WO 1998017315A3 US 9718956 W US9718956 W US 9718956W WO 9817315 A3 WO9817315 A3 WO 9817315A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
permeation enhancer
methods
drug delivery
devices
Prior art date
Application number
PCT/US1997/018956
Other languages
French (fr)
Other versions
WO1998017315A2 (en
Inventor
Eun Soo Lee
Su Il Yum
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Priority to AU49907/97A priority Critical patent/AU4990797A/en
Priority to DK97912815T priority patent/DK0934078T3/en
Priority to CA002264687A priority patent/CA2264687C/en
Priority to JP10519563A priority patent/JP2001502693A/en
Priority to AT97912815T priority patent/ATE229817T1/en
Priority to EP97912815A priority patent/EP0934078B1/en
Priority to DE69718037T priority patent/DE69718037T2/en
Publication of WO1998017315A2 publication Critical patent/WO1998017315A2/en
Publication of WO1998017315A3 publication Critical patent/WO1998017315A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Abstract

The present invention is directed to the transdermal administration of at least one drug together with a suitable amount of a permeation enhancer comprising monoalkyl ethers of polyethyleneglycol and their alkyl or aryl carboxylic acid esters and carboxymethyl ethers. The invention includes a transdermal drug delivery device comprising a matrix adapted to be placed in drug- and- permeation enhancer- transmitting relation with a skin site. The matrix contains sufficient amounts of the permeation enhancer and drug, in combination, to continuously administer drug to the systemic circulation of a patient at a therapeutically effective rate. The invention is also directed to compositions and methods for transdermal administration of at least one drug together with a permeation enhancer of this invention, alone or in combination with other enhancers.
PCT/US1997/018956 1996-10-24 1997-10-23 Permeation enhancers for transdermal drug delivery compositions, devices, and methods WO1998017315A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU49907/97A AU4990797A (en) 1996-10-24 1997-10-23 Permeation enhancers for transdermal drug delivery compositions, devices, and methods
DK97912815T DK0934078T3 (en) 1996-10-24 1997-10-23 Permeability promoters for transdermal administration of active substances, devices and processes for their preparation
CA002264687A CA2264687C (en) 1996-10-24 1997-10-23 Permeation enhancers for transdermal drug delivery compositions, devices, and methods
JP10519563A JP2001502693A (en) 1996-10-24 1997-10-23 Permeation enhancers suitable for transdermal drug administration compositions, devices, and methods
AT97912815T ATE229817T1 (en) 1996-10-24 1997-10-23 PENETRATION-PROMOTING SUBSTANCES FOR THE TRANSDERMAL ADMINISTRATION OF ACTIVE INGREDIENTS, DEVICES AND METHOD FOR THE PRODUCTION
EP97912815A EP0934078B1 (en) 1996-10-24 1997-10-23 Permeation enhancers for transdermal drug delivery compositions, devices, and methods
DE69718037T DE69718037T2 (en) 1996-10-24 1997-10-23 PENETRATION-PROMOTING SUBSTANCES FOR THE TRANSDERMAL ADMINISTRATION OF ACTIVE SUBSTANCES, DEVICES AND METHODS FOR THE PRODUCTION THEREOF

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3042496P 1996-10-24 1996-10-24
US60/030,424 1996-10-24

Publications (2)

Publication Number Publication Date
WO1998017315A2 WO1998017315A2 (en) 1998-04-30
WO1998017315A3 true WO1998017315A3 (en) 1998-07-02

Family

ID=21854141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/018956 WO1998017315A2 (en) 1996-10-24 1997-10-23 Permeation enhancers for transdermal drug delivery compositions, devices, and methods

Country Status (10)

Country Link
US (1) US6004578A (en)
EP (1) EP0934078B1 (en)
JP (1) JP2001502693A (en)
AT (1) ATE229817T1 (en)
AU (1) AU4990797A (en)
CA (1) CA2264687C (en)
DE (1) DE69718037T2 (en)
DK (1) DK0934078T3 (en)
ES (1) ES2191834T3 (en)
WO (1) WO1998017315A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518417A (en) * 1998-06-25 2002-06-25 ラヴィファム ラボラトリーズ インコーポレーテッド Braces and methods for treating erectile dysfunction
US20070191320A1 (en) * 1998-12-10 2007-08-16 Nexmed Holdings, Inc. Methods of treatment for female sexual arousal disorder
US6486207B2 (en) * 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6825234B2 (en) * 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
CA2361424C (en) † 1999-02-08 2009-04-28 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
WO2000048634A1 (en) * 1999-02-19 2000-08-24 Takeda Chemical Industries, Ltd. Percutaneous absorption preparations of compound having angiotensin ii receptor antagonism
WO2001013950A1 (en) 1999-08-20 2001-03-01 Takeda Chemical Industries, Ltd. Percutaneous absorption agents
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
WO2002054996A2 (en) * 2000-10-23 2002-07-18 Euro Celtique Sa Terazosin transdermal device and methods
RU2708563C2 (en) * 2001-03-16 2019-12-10 Алза Корпорейшн Transdermal patch for administering fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
US6521613B2 (en) 2001-04-10 2003-02-18 Allergan, Inc. Lactam compounds for penetration enhancement
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
JP4116447B2 (en) 2001-05-01 2008-07-09 エイ．ブイ．トップチーブ インスティテュート オブ ペトロケミカル シンセシス Hydrogel composition
ES2587187T3 (en) 2001-05-01 2016-10-21 A. V. Topchiev Institute Of Petrochemical Synthesis Biphasic water absorbent bioadhesive composition
DE10154324A1 (en) * 2001-11-06 2003-08-07 Merz Pharma Gmbh & Co Kgaa Topically applicable compositions with external active substance depot formation, their production and their use
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
KR20050050615A (en) 2002-04-23 2005-05-31 알자 코포레이션 Transdermal analgesic systems with reduced abuse potential
US20040033255A1 (en) 2002-06-10 2004-02-19 Baker Carl J. Transdermal delivery device disposal system
DE60326354D1 (en) * 2002-08-20 2009-04-09 Euro Celtique Sa TRANSDERMAL DOSAGE FORM CONTAINING AN ACTIVE SUBSTANCE AND AN ANTAGONIST IN FREE BASE AND SALT FORM
CN100340395C (en) * 2002-08-30 2007-10-03 阿尔扎公司 Multilaminate backing construction
US20040057907A1 (en) * 2002-09-23 2004-03-25 Leonard Mackles Dri-nasal sprays
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd Transdermal delivery system for anti-emetic medication
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd Transdermal delivery system for water insoluble drugs
CA2453013C (en) * 2002-12-13 2011-02-15 Gary W. Cleary Dermal, transdermal, mucosal or transmucosal ingredient delivery devices
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20040202708A1 (en) * 2003-04-14 2004-10-14 3M Innovative Properties Company Transdermal drug delivery device with translucent inorganic barrier layer
EP2316440A1 (en) 2003-04-30 2011-05-04 Purdue Pharma L.P. Transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer and one fluid communication between the surface of the active agent and the adverse agent
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US20040219198A1 (en) * 2003-05-01 2004-11-04 3M Innovative Properties Company Transdermal drug delivery device with multilayer backing
US7563748B2 (en) * 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
US7888546B2 (en) 2003-07-03 2011-02-15 Corium International, Inc. Wound dressing, ingredient delivery device and IV hold-down, and method relating to same
WO2005011644A1 (en) 2003-07-28 2005-02-10 Alza Corporation Transdermal warfarin-containing delivery system
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
CN1909892A (en) 2003-10-30 2007-02-07 阿尔扎公司 Transdermal analgesic systems having reduced abuse potential
US8658201B2 (en) 2004-01-30 2014-02-25 Corium International, Inc. Rapidly dissolving film for delivery of an active agent
ES2526700T3 (en) 2004-08-05 2015-01-14 Corium International, Inc. Adhesive composition
US20070269522A1 (en) * 2004-08-20 2007-11-22 Wold Chad R Transdermal Drug Delivery Device with Translucent Protective Film
WO2006044590A1 (en) * 2004-10-19 2006-04-27 3M Innovative Properties Company Method for the manufacture of pressure sensitive adhesives
CN102085198B (en) 2004-10-21 2014-06-04 杜雷科特公司 Transdermal delivery systems
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20060216350A1 (en) * 2005-03-24 2006-09-28 Dow Gordon J Ganglionic blocking agents for the treatment of epithelial diseases
DE602006016441D1 (en) * 2005-05-13 2010-10-07 Alza Corp MULTILAYER DRUG DISPOSAL SYSTEM WITH BARRIER AGAINST RESERVOIR MATERIAL FLOW
CN101232875B (en) 2005-06-10 2014-06-25 3M创新有限公司 Method for handling adhesive laminate sections
US9056061B2 (en) * 2005-09-23 2015-06-16 Alza Corporation Transdermal nicotine salt delivery system
EP1937226A2 (en) * 2005-09-23 2008-07-02 Alza Corporation Transdermal galantamine delivery system
WO2007035942A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal risperidone delivery system
WO2007035939A2 (en) 2005-09-23 2007-03-29 Alza Corporation High enhancer-loading polyacrylate formulation for transdermal applications
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
WO2007046102A2 (en) 2005-10-19 2007-04-26 Menni Menashe Zinger Methods for the treatment of hyperhidrosis
US20070278289A1 (en) * 2006-05-31 2007-12-06 Toshiba Tec Kabushiki Kaisha Payment adjusting apparatus and program therefor
ES2422864T3 (en) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Osmotic release systems and piston units
US8940326B2 (en) 2007-03-19 2015-01-27 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
RU2440097C2 (en) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Method of treating insulin-independent diabetes and obesity, osmotic delivery system and method for making it
US9909098B2 (en) 2007-08-06 2018-03-06 The Regents Of The University Of California Methods of tissue-based diagnosis
US9814422B2 (en) 2007-08-06 2017-11-14 The Regents Of The University Of California Compositions for solubilizing cells and/or tissue
CN101902996B (en) * 2007-10-15 2014-11-26 阿尔扎公司 Once-a-day replacement transdermal administration of fentanyl
EP2328582A4 (en) * 2008-09-30 2012-02-22 Teikoku Pharma Usa Inc Transdermal extended-delivery donepezil compositions and methods for using the same
US8784879B2 (en) 2009-01-14 2014-07-22 Corium International, Inc. Transdermal administration of tamsulosin
WO2010091198A1 (en) 2009-02-06 2010-08-12 University Of Southern California Therapeutic compositions comprising monoterpenes
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
JP2013512257A (en) 2009-11-30 2013-04-11 スリーエム イノベイティブ プロパティズ カンパニー Compatible barrier sheet, method and article
CN104744215B (en) 2010-03-03 2019-03-15 尼昂克技术公司 Pharmaceutical composition comprising monoterpene
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
RU2018135967A (en) * 2011-03-31 2018-11-14 Акорда Терапьютикс, Инк. INTRASASAL PHARMACEUTICAL COMPOSITIONS BASED ON BENZODIAZEPINE
EP2790684B1 (en) 2011-12-16 2016-10-12 3M Innovative Properties Company Foldable adhesive composite dressing
JP6576039B2 (en) 2011-12-21 2019-09-18 スリーエム イノベイティブ プロパティズ カンパニー Adhesive patch assembly having an overlay liner and systems and methods for making the same
WO2013096026A1 (en) 2011-12-21 2013-06-27 3M Innovative Properties Company Transdermal adhesive patch assembly with removable microneedle array and method of using same
EP3056559B1 (en) * 2012-05-16 2019-07-10 The Regents Of The University Of California Compositions for solubilizing cells and/or tissue
US9782574B2 (en) 2012-10-10 2017-10-10 3M Innovative Properties Company Force-controlled applicator for applying a microneedle device to skin
EP2919849B1 (en) 2012-11-16 2021-01-06 Kindeva Drug Delivery L.P. Force-controlled applicator for applying a microneedle device to skin
US20160271380A1 (en) 2013-03-22 2016-09-22 3M Innovative Properties Company Microneedle applicator comprising a counter assembly
EP3003457B8 (en) 2013-05-31 2021-02-24 Kindeva Drug Delivery L.P. Microneedle injection and infusion apparatus
MX353241B (en) 2013-05-31 2018-01-05 3M Innovative Properties Co Microneedle injection apparatus comprising an inverted actuator.
EP3003458B1 (en) 2013-05-31 2019-12-04 3M Innovative Properties Company Microneedle injection apparatus comprising a dual cover
CN105491982B (en) 2013-08-12 2019-09-10 3M创新有限公司 For enhancing the peptide of transdermal delivery
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3020398A1 (en) 2014-11-17 2016-05-18 Nitto Denko Corporation Compounds and formulations for reducing scarring
CN107107598B (en) 2014-12-18 2019-11-22 3M创新有限公司 The method for handling bonded laminate patch
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
CR20180128A (en) * 2015-08-05 2018-04-24 Childrens Medical Center COMPOSITIONS WITH PERMEATION POTENTIALS FOR DRUG SUPPLY
WO2017136303A1 (en) 2016-02-05 2017-08-10 3M Innovative Properties Company Transdermal drug delivery systems with fluorosilicone release liners
EP3441382B1 (en) * 2016-04-05 2023-08-30 Moresco Corporation Oxa acid compound
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2017223402A1 (en) 2016-06-23 2017-12-28 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
AU2017302306A1 (en) 2016-07-27 2019-02-14 Corium, LLC. Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug
KR102508993B1 (en) 2016-07-27 2023-03-10 코리움, 인크. Memantine Transdermal Delivery System
EP3490559A1 (en) 2016-07-27 2019-06-05 Corium International, Inc. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
EP3287462A1 (en) 2016-08-25 2018-02-28 Nitto Denko Corporation Isosorbide derivatives to treat bacterial biofilms
KR20190104039A (en) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Methods Including Continuous Administration of GLP-1 Receptor Agonists and Co-administration of Drugs
US11219688B2 (en) * 2017-03-03 2022-01-11 Moresco Corporation Absorption promoter and use for same
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
CA3225993A1 (en) 2018-02-08 2019-08-15 University Of Southern California The use of monoterpene, sesquiterpene, or their derivatives to permeabilize the blood brain barrier
CA3095873A1 (en) * 2018-04-05 2019-10-10 Steven Robert ERBST Therapeutic elastic bandage for modulating the endocannabinoid system
WO2019217536A1 (en) * 2018-05-08 2019-11-14 University Of Connecticut Long-acting local anesthetic formulation
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
EP4003256A4 (en) * 2019-07-30 2023-05-24 Kai P. Leung Layered composite for scar treatment and prevention

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020378A1 (en) * 1991-05-15 1992-11-26 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Penetration-promoting substance
WO1996019976A1 (en) * 1994-12-24 1996-07-04 Pacific Corporation Medicinal patches for percutaneous administration
WO1996040139A1 (en) * 1995-06-07 1996-12-19 Alza Corporation Novel formulations for transdermal delivery of pergolide

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1011949A (en) * 1964-10-27 1965-12-01 Vacu Blast Ltd Centrifugal wheel blasting machine
US3527864A (en) * 1966-11-18 1970-09-08 Procter & Gamble Compositions for topical application to animal tissue and method of enhancing penetration thereof
US3472931A (en) * 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3731663A (en) * 1971-01-08 1973-05-08 Hollins J R Vehicle engine fuel control accelerator override
US3903256A (en) * 1972-02-07 1975-09-02 Procter & Gamble Compositions for topical application of animal tissue and method of enhancing penetration thereof
US3896238A (en) * 1972-04-05 1975-07-22 Procter & Gamble Dermatological compositions
US3952099A (en) * 1973-03-13 1976-04-20 The Procter & Gamble Company Dermatological compositions
US4046886A (en) * 1975-01-17 1977-09-06 The Procter & Gamble Company Dermatological compositions
US4144317A (en) * 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4130667A (en) * 1976-01-12 1978-12-19 The Procter & Gamble Company Dermatological compositions
US4335115A (en) * 1976-11-01 1982-06-15 The Procter & Gamble Company Anti-acne composition
US4299826A (en) * 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
US4286592A (en) * 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) * 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
FR2495934A1 (en) * 1980-12-15 1982-06-18 Cird COMPOSITION FOR THE TREATMENT OF PSORIASIS BASED ON SUBSTITUTED-1,8-DIHYDROXY-1,8-ANTHRONE-9
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4343798A (en) * 1981-06-23 1982-08-10 The Procter & Gamble Company Topical antimicrobial anti-inflammatory compositions
US4849226A (en) * 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
US4435180A (en) * 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
US4559222A (en) * 1983-05-04 1985-12-17 Alza Corporation Matrix composition for transdermal therapeutic system
US4573999A (en) * 1983-10-14 1986-03-04 Netto Daniel J Human breast prosthesis
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US4900555A (en) * 1987-02-26 1990-02-13 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4865848A (en) * 1987-02-26 1989-09-12 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4764379A (en) * 1987-08-24 1988-08-16 Alza Corporation Transdermal drug delivery device with dual permeation enhancers
US4820720A (en) * 1987-08-24 1989-04-11 Alza Corporation Transdermal drug composition with dual permeation enhancers
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4863738A (en) * 1987-11-23 1989-09-05 Alza Corporation Skin permeation enhancer compositions using glycerol monooleate
US5378730A (en) * 1988-06-09 1995-01-03 Alza Corporation Permeation enhancer comprising ethanol and monoglycerides
US5004610A (en) * 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US5053327A (en) * 1988-09-20 1991-10-01 The United States Of America As Represented By The Secretary Of Agriculture High affinity monoclonal antibodies to bowman-birk inhibitor and immunoassay methods
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
JP2820306B2 (en) * 1990-02-27 1998-11-05 積水化学工業株式会社 Transdermal formulation
US5314694A (en) * 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
WO1993023025A1 (en) * 1992-05-13 1993-11-25 Alza Corporation Transdermal administration of oxybutynin
KR960704579A (en) * 1993-09-29 1996-10-09 에드워드 엘. 만델 Monoglyceride / lactate Ester Permeation Enhancer for Oxybutynin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020378A1 (en) * 1991-05-15 1992-11-26 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Penetration-promoting substance
WO1996019976A1 (en) * 1994-12-24 1996-07-04 Pacific Corporation Medicinal patches for percutaneous administration
WO1996040139A1 (en) * 1995-06-07 1996-12-19 Alza Corporation Novel formulations for transdermal delivery of pergolide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KADIR R. ET AL: "Penetration of theophylline and adenosine into excised human skin from binary and ternary vehicles: effect of a nonionic surfactant", J. OF PHARM. SCIENCES, vol. 78, no. 2, 1989, pages 149 - 153, XP002063173 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Also Published As

Publication number Publication date
JP2001502693A (en) 2001-02-27
ES2191834T3 (en) 2003-09-16
EP0934078A2 (en) 1999-08-11
WO1998017315A2 (en) 1998-04-30
AU4990797A (en) 1998-05-15
CA2264687C (en) 2006-04-25
US6004578A (en) 1999-12-21
DE69718037D1 (en) 2003-01-30
EP0934078B1 (en) 2002-12-18
CA2264687A1 (en) 1998-04-30
DK0934078T3 (en) 2003-04-14
ATE229817T1 (en) 2003-01-15
DE69718037T2 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
WO1998017315A3 (en) Permeation enhancers for transdermal drug delivery compositions, devices, and methods
MX9709162A (en) Skin permeation enhancer compositions using acyl lactylates.
ES2137261T3 (en) TRANSDERMIC ADMINISTRATION OF OXYBUTININE.
GB2316004B (en) Novel formulations for transdermal delivery of pergolide
CY2503B1 (en) Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate.
FR11C0006I1 (en) IMPROVED DRUG DELIVERY ON MUCOSA
ZA944608B (en) Incorporating poly-N-vinyl amide in a transdermal system
AU2313297A (en) Transdermally administered dextromethorphan as antitussive agent
CA2333076A1 (en) Topical application of muscarinic analgesic drugs such as neostigmine
HK1036594A1 (en) Formulations for the transdermal administration offenoldopam.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2264687

Country of ref document: CA

Ref country code: CA

Ref document number: 2264687

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 519563

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997912815

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997912815

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1997912815

Country of ref document: EP